• Something wrong with this record ?

PV Isolation Using a Spherical Array PFA Catheter: Application Repetition and Lesion Durability (PULSE-EU Study)

MK. Turagam, P. Neuzil, J. Petru, M. Funasako, JS. Koruth, D. Reinders, J. Skoda, S. Kralovec, VY. Reddy

. 2023 ; 9 (5) : 638-648. [pub] 20230203

Language English Country United States

Document type Journal Article

BACKGROUND: Preclinical studies have revealed that pulsed field ablation (PFA) lesion dimensions increase with repetitive applications at a similar electric field. OBJECTIVES: This study investigated whether pulmonary vein isolation (PVI) durability varies with single vs repetitive pulsed field (PF) applications. METHODS: Atrial fibrillation patients underwent PVI using a spherical multielectrode array PFA catheter delivered with a 19-F deflectable sheath under intracardiac echocardiographic guidance. Esophagogastroduodenoscopy and brain magnetic resonance imaging were performed within 1 to 3 days, and invasive remapping at ∼2 to 3 months. RESULTS: The patient cohort (n = 21; age 63 ± 11 years; 67% women) underwent PVI in either of 2 groups: group 1 (n = 11)-single PF application/PV; and group 2 (n = 10)-3 PF applications/PV. In both groups, PVI was acutely successful in all (100%) patients. Despite significantly longer pulse delivery times (75.2 ± 7.4 s/patient vs 24.5 ± 5.5 s/patient) the procedure times (73.2 ± 13.7 minutes vs 93.7 ± 18.5 minutes) were shorter with group 2 vs group 1. There was no stroke/transient ischemic attack, pericardial effusion, phrenic nerve injury, or esophageal complications. Esophagogastroduodenoscopy was normal in both groups of patients (n = 9). Screening brain magnetic resonance imaging revealed asymptomatic cerebral lesions (diffusion weighted imaging+/fluid attenuated inversion recovery-) in 3 of 16 (18.7%) patients. PV remapping revealed durable PVI in 62.5% PVs in group 1 (n = 10), compared with all 100% PVs in group 2 (n = 9); this translates to all PVs being durably isolated in 30% vs 100% (P < 0.05) of patients in groups 1 and 2, respectively. CONCLUSIONS: In his first-in-human trial, the "single-shot" spherical array PFA catheter was shown to safely isolate PVs. Repetitive PF application is key for lesion consolidation to maximize PVI durability.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011597
003      
CZ-PrNML
005      
20230801133155.0
007      
ta
008      
230718s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jacep.2023.01.009 $2 doi
035    __
$a (PubMed)36828771
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Turagam, Mohit K $u Icahn School of Medicine at Mount Sinai, New York, New York, USA
245    10
$a PV Isolation Using a Spherical Array PFA Catheter: Application Repetition and Lesion Durability (PULSE-EU Study) / $c MK. Turagam, P. Neuzil, J. Petru, M. Funasako, JS. Koruth, D. Reinders, J. Skoda, S. Kralovec, VY. Reddy
520    9_
$a BACKGROUND: Preclinical studies have revealed that pulsed field ablation (PFA) lesion dimensions increase with repetitive applications at a similar electric field. OBJECTIVES: This study investigated whether pulmonary vein isolation (PVI) durability varies with single vs repetitive pulsed field (PF) applications. METHODS: Atrial fibrillation patients underwent PVI using a spherical multielectrode array PFA catheter delivered with a 19-F deflectable sheath under intracardiac echocardiographic guidance. Esophagogastroduodenoscopy and brain magnetic resonance imaging were performed within 1 to 3 days, and invasive remapping at ∼2 to 3 months. RESULTS: The patient cohort (n = 21; age 63 ± 11 years; 67% women) underwent PVI in either of 2 groups: group 1 (n = 11)-single PF application/PV; and group 2 (n = 10)-3 PF applications/PV. In both groups, PVI was acutely successful in all (100%) patients. Despite significantly longer pulse delivery times (75.2 ± 7.4 s/patient vs 24.5 ± 5.5 s/patient) the procedure times (73.2 ± 13.7 minutes vs 93.7 ± 18.5 minutes) were shorter with group 2 vs group 1. There was no stroke/transient ischemic attack, pericardial effusion, phrenic nerve injury, or esophageal complications. Esophagogastroduodenoscopy was normal in both groups of patients (n = 9). Screening brain magnetic resonance imaging revealed asymptomatic cerebral lesions (diffusion weighted imaging+/fluid attenuated inversion recovery-) in 3 of 16 (18.7%) patients. PV remapping revealed durable PVI in 62.5% PVs in group 1 (n = 10), compared with all 100% PVs in group 2 (n = 9); this translates to all PVs being durably isolated in 30% vs 100% (P < 0.05) of patients in groups 1 and 2, respectively. CONCLUSIONS: In his first-in-human trial, the "single-shot" spherical array PFA catheter was shown to safely isolate PVs. Repetitive PF application is key for lesion consolidation to maximize PVI durability.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a výsledek terapie $7 D016896
650    _2
$a časové faktory $7 D013997
650    12
$a katetrizační ablace $x metody $7 D017115
650    _2
$a srdeční frekvence $7 D006339
650    _2
$a katétry $7 D057785
650    12
$a venae pulmonales $x chirurgie $7 D011667
655    _2
$a časopisecké články $7 D016428
700    1_
$a Neuzil, Petr $u Homolka Hospital, Prague, Czech Republic
700    1_
$a Petru, Jan $u Homolka Hospital, Prague, Czech Republic
700    1_
$a Funasako, Moritoshi $u Homolka Hospital, Prague, Czech Republic
700    1_
$a Koruth, Jacob S $u Icahn School of Medicine at Mount Sinai, New York, New York, USA
700    1_
$a Reinders, Daniel $u Kardium Inc, Burnaby, British Columbia, Canada
700    1_
$a Skoda, Jan $u Homolka Hospital, Prague, Czech Republic
700    1_
$a Kralovec, Stepan $u Homolka Hospital, Prague, Czech Republic
700    1_
$a Reddy, Vivek Y $u Icahn School of Medicine at Mount Sinai, New York, New York, USA; Homolka Hospital, Prague, Czech Republic. Electronic address: vivek.reddy@mountsinai.org
773    0_
$w MED00193518 $t JACC. Clinical electrophysiology $x 2405-5018 $g Roč. 9, č. 5 (2023), s. 638-648
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36828771 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801133152 $b ABA008
999    __
$a ok $b bmc $g 1963809 $s 1197862
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 9 $c 5 $d 638-648 $e 20230203 $i 2405-5018 $m JACC. Clinical electrophysiology $n JACC Clin Electrophysiol $x MED00193518
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...